NO934163D0 - HER4 human reseptor-tyrosinkinase - Google Patents
HER4 human reseptor-tyrosinkinaseInfo
- Publication number
- NO934163D0 NO934163D0 NO934163A NO934163A NO934163D0 NO 934163 D0 NO934163 D0 NO 934163D0 NO 934163 A NO934163 A NO 934163A NO 934163 A NO934163 A NO 934163A NO 934163 D0 NO934163 D0 NO 934163D0
- Authority
- NO
- Norway
- Prior art keywords
- tyrosine kinase
- receptor tyrosine
- human receptor
- her4
- her4 human
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/4756—Neuregulins, i.e. p185erbB2 ligands, glial growth factor, heregulin, ARIA, neu differentiation factor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/475—Assays involving growth factors
- G01N2333/4756—Neuregulins, i.e. p185erbB2 ligands, glial growth factor, heregulin, ARIA, neu differentiation factor
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US98116592A | 1992-11-24 | 1992-11-24 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| NO934163D0 true NO934163D0 (no) | 1993-11-18 |
| NO934163L NO934163L (no) | 1994-05-25 |
Family
ID=25528166
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO934163A NO934163L (no) | 1992-11-24 | 1993-11-18 | HER4 human reseptor-tyrosinkinase |
Country Status (8)
| Country | Link |
|---|---|
| EP (1) | EP0599274A1 (no) |
| JP (1) | JPH07132084A (no) |
| AU (1) | AU676502B2 (no) |
| CA (1) | CA2103323A1 (no) |
| FI (1) | FI935175A (no) |
| IL (1) | IL107661A0 (no) |
| MX (1) | MX9307317A (no) |
| NO (1) | NO934163L (no) |
Families Citing this family (61)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5811098A (en) * | 1992-11-24 | 1998-09-22 | Bristol-Myers Squibb Company | Antibodies to HER4, human receptor tyrosine kinase |
| AU2963395A (en) * | 1994-07-20 | 1996-02-16 | Genetics Institute Inc. | Mlk receptor tyrosine kinases |
| WO1996012019A2 (en) * | 1994-10-14 | 1996-04-25 | Bristol-Myers Squibb Company | Her4 human receptor tyrosine kinase or the epidermal growth factor receptor family |
| AUPM959894A0 (en) * | 1994-11-22 | 1994-12-15 | Crc For Biopharmaceutical Research Pty Ltd | Fusion proteins with cytotoxic activity against cells overexpressing erbb2-4 |
| AUPN274295A0 (en) * | 1995-05-02 | 1995-05-25 | Garvan Institute Of Medical Research | GDU, a novel signalling protein |
| US6465623B2 (en) | 1995-05-02 | 2002-10-15 | Garvan Institute Of Medical Research | GDU, a novel signalling protein |
| US6267958B1 (en) | 1995-07-27 | 2001-07-31 | Genentech, Inc. | Protein formulation |
| US6685940B2 (en) | 1995-07-27 | 2004-02-03 | Genentech, Inc. | Protein formulation |
| US5968511A (en) * | 1996-03-27 | 1999-10-19 | Genentech, Inc. | ErbB3 antibodies |
| AU727606B2 (en) | 1996-07-12 | 2000-12-14 | Genentech Inc. | Gamma-heregulin |
| US7371376B1 (en) | 1996-10-18 | 2008-05-13 | Genentech, Inc. | Anti-ErbB2 antibodies |
| ATE427353T1 (de) | 1997-02-10 | 2009-04-15 | Genentech Inc | Heregulin varianten |
| US6136558A (en) * | 1997-02-10 | 2000-10-24 | Genentech, Inc. | Heregulin variants |
| US6777534B1 (en) | 1997-12-09 | 2004-08-17 | Children's Medical Center Corporation | Peptide antagonists of vascular endothelial growth factor |
| ZA9811162B (en) | 1997-12-12 | 2000-06-07 | Genentech Inc | Treatment with anti-ERBB2 antibodies. |
| US20010023241A1 (en) | 1998-02-04 | 2001-09-20 | Sliwkowski Mark X. | Use of heregulin as a growth factor |
| EP1941905A1 (en) | 1998-03-27 | 2008-07-09 | Genentech, Inc. | APO-2 Ligand-anti-her-2 antibody synergism |
| BR122014028365B8 (pt) | 1999-06-25 | 2021-07-06 | Genentech Inc | artigo industrializado compreendendo um primeiro recipiente que compreende uma composição de humab4d5-8 nele contida e um segundo recipiente que compreende uma composição rhumab 2c4 nele contida |
| HU230586B1 (hu) | 1999-06-25 | 2017-02-28 | Genentech, Inc. | Anti-ErbB antitest/maytansinoid konjugátumok alkalmazása rákos betegségek kezelésére szolgáló gyógyszer előállítására |
| US6949245B1 (en) | 1999-06-25 | 2005-09-27 | Genentech, Inc. | Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies |
| US7041292B1 (en) | 1999-06-25 | 2006-05-09 | Genentech, Inc. | Treating prostate cancer with anti-ErbB2 antibodies |
| US6927203B1 (en) | 1999-08-17 | 2005-08-09 | Purdue Research Foundation | Treatment of metastatic disease |
| JP2003516930A (ja) * | 1999-08-17 | 2003-05-20 | パーデュー・リサーチ・ファウンデーション | 転移性疾患の治療 |
| DE60042693D1 (de) | 1999-08-27 | 2009-09-17 | Genentech Inc | Dosierung für die behandlung mit anti erbb2-antikörpern |
| NZ521540A (en) | 2000-04-11 | 2004-09-24 | Genentech Inc | Multivalent antibodies and uses therefor |
| JP2003534292A (ja) | 2000-05-19 | 2003-11-18 | ジェネンテック・インコーポレーテッド | Ｅｒｂｂアンタゴニスト癌治療に対する有効な応答の可能性を向上させるための遺伝子検出アッセイ |
| US6255111B1 (en) | 2000-07-31 | 2001-07-03 | Isis Pharmaceuticals, Inc. | Antisense modulation of Her-4 expression |
| US20020119148A1 (en) | 2000-09-01 | 2002-08-29 | Gerritsen Mary E. | ErbB4 antagonists |
| US20050276812A1 (en) | 2004-06-01 | 2005-12-15 | Genentech, Inc. | Antibody-drug conjugates and methods |
| MXPA05000403A (es) | 2002-07-15 | 2005-07-22 | Genentech Inc | Metodos para identificar tumores que responden al tratamiento con anticuerpos contra erbb2. |
| BR122018071968B8 (pt) | 2003-11-06 | 2021-07-27 | Seattle Genetics Inc | conjugado de anticorpo-droga, composição farmacêutica, artigo de manufatura e uso de um conjugado de anticorpo-droga |
| AU2005232657B2 (en) | 2004-04-08 | 2010-12-16 | David B. Agus | ErbB antagonists for pain therapy |
| NZ580115A (en) | 2004-09-23 | 2010-10-29 | Genentech Inc | Cysteine engineered antibody light chains and conjugates |
| US20100111856A1 (en) | 2004-09-23 | 2010-05-06 | Herman Gill | Zirconium-radiolabeled, cysteine engineered antibody conjugates |
| JO3000B1 (ar) | 2004-10-20 | 2016-09-05 | Genentech Inc | مركبات أجسام مضادة . |
| US7939267B2 (en) | 2004-11-04 | 2011-05-10 | Laboratory Corporation Of America Holdings | Detection of activation of endothelial cells as surrogate marker for angiogenesis |
| US7449184B2 (en) | 2005-01-21 | 2008-11-11 | Genentech, Inc. | Fixed dosing of HER antibodies |
| PT1850874E (pt) | 2005-02-23 | 2013-12-02 | Genentech Inc | Extensão de tempo até a progressão da doença ou sobrevivência em pacientes com cancro de ovário usando pertuzumab |
| AU2007281774A1 (en) | 2006-08-04 | 2008-02-14 | Astrazeneca Ab | Human antibodies to ErbB 2 |
| PE20090681A1 (es) | 2007-03-02 | 2009-06-10 | Genentech Inc | Prediccion de respuesta a un inhibidor her |
| CA2690334C (en) | 2007-06-08 | 2017-02-14 | Genentech, Inc. | Gene expression markers of tumor resistance to her2 inhibitor treatment |
| TWI472339B (zh) | 2008-01-30 | 2015-02-11 | Genentech Inc | 包含結合至ｈｅｒ２結構域ii之抗體及其酸性變異體的組合物 |
| KR101789338B1 (ko) | 2008-11-25 | 2017-10-23 | 제넨테크, 인크. | 이소형 특이적 항-ｈｅｒ４ 항체 |
| ES2572728T3 (es) | 2009-03-20 | 2016-06-02 | F. Hoffmann-La Roche Ag | Anticuerpos anti-HER biespecíficos |
| JP5705836B2 (ja) | 2009-05-29 | 2015-04-22 | エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト | Ｈｅｒ２を発現する胃癌患者のｈｅｒ２シグナル伝達のためのモジュレーター |
| CA2781682A1 (en) | 2009-12-04 | 2011-06-09 | Genentech, Inc. | Multispecific antibodies, antibody analogs, compositions, and methods |
| WO2011146568A1 (en) | 2010-05-19 | 2011-11-24 | Genentech, Inc. | Predicting response to a her inhibitor |
| EA036314B1 (ru) | 2010-08-20 | 2020-10-26 | Новартис Аг | Выделенные антитела к рецептору эпидермального фактора роста-3 (her3) и их фрагменты, фармацевтическая композиция, содержащая эти антитела и фрагменты, и их применение для лечения рака |
| EP2655413B1 (en) | 2010-12-23 | 2019-01-16 | F.Hoffmann-La Roche Ag | Polypeptide-polynucleotide-complex and its use in targeted effector moiety delivery |
| CA2845179A1 (en) | 2011-08-31 | 2013-03-07 | Genentech, Inc. | Diagnostic markers |
| CA2850667A1 (en) | 2011-10-04 | 2013-04-11 | Expression Pathology, Inc. | Srm/mrm assay for the receptor tyrosine-protein kinase erbb-4 protein (her4) |
| RU2019103083A (ru) | 2011-11-30 | 2019-03-22 | Дженентек, Инк. | МУТАЦИИ ErbB3 ПРИ РАКЕ |
| EA036739B1 (ru) | 2011-12-05 | 2020-12-15 | Новартис Аг | Антитела к рецептору эпидермального фактора роста 3 (her3) |
| US9376715B2 (en) | 2011-12-09 | 2016-06-28 | Roche Molecular Systems, Inc | Methods for detecting mutations in the catalytic subunit of the phosphoinositol-3 kinase (PIK3CA) gene |
| EP2831115A1 (en) | 2012-03-27 | 2015-02-04 | F. Hoffmann-La Roche AG | Diagnosis and treatments relating to her3 inhibitors |
| BR112015012644A2 (pt) | 2012-11-30 | 2017-12-19 | Hoffmann La Roche | método para determinar a necessidade de um paciente com câncer, método de tratamento do câncer, composição farmacêutica, uso de um ácido nucleico ou anticorpo e kit; |
| RU2016141385A (ru) | 2014-03-24 | 2018-04-28 | Дженентек, Инк. | Лечение рака антагонистами с-мет и их корреляция с экспрессией hgf |
| EP3169708B1 (en) | 2014-07-16 | 2019-03-20 | Dana-Farber Cancer Institute Inc. et Al. | Her3 inhibition in low-grade serous ovarian cancers |
| EP3454863A1 (en) | 2016-05-10 | 2019-03-20 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Combinations therapies for the treatment of cancer |
| TW201902509A (zh) | 2017-04-24 | 2019-01-16 | 美商建南德克公司 | Erbb2/her2突變 |
| EP4180061A1 (en) | 2021-11-10 | 2023-05-17 | Nerviano Medical Sciences S.r.l. | Anthracycline derivative linker reagents, antibody-drug conjugates and methods |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2055441C (en) * | 1989-05-19 | 2003-01-07 | Robert M. Hudziak | Her2 extracellular domain |
| EP0444961A1 (en) * | 1990-03-02 | 1991-09-04 | Bristol-Myers Squibb Company | Her3: A novel EGF receptor homolog |
| IL101943A0 (en) * | 1991-05-24 | 1992-12-30 | Genentech Inc | Structure,production and use of heregulin |
-
1993
- 1993-11-17 CA CA002103323A patent/CA2103323A1/en not_active Abandoned
- 1993-11-18 NO NO934163A patent/NO934163L/no not_active Application Discontinuation
- 1993-11-18 IL IL10766193A patent/IL107661A0/xx unknown
- 1993-11-19 AU AU51804/93A patent/AU676502B2/en not_active Ceased
- 1993-11-22 FI FI935175A patent/FI935175A/fi not_active IP Right Cessation
- 1993-11-23 EP EP93118837A patent/EP0599274A1/en not_active Withdrawn
- 1993-11-23 MX MX9307317A patent/MX9307317A/es unknown
- 1993-11-24 JP JP5317374A patent/JPH07132084A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CA2103323A1 (en) | 1994-05-25 |
| FI935175A0 (fi) | 1993-11-22 |
| IL107661A0 (en) | 1994-02-27 |
| NO934163L (no) | 1994-05-25 |
| AU5180493A (en) | 1994-06-09 |
| EP0599274A1 (en) | 1994-06-01 |
| FI935175A (fi) | 1994-05-25 |
| JPH07132084A (ja) | 1995-05-23 |
| MX9307317A (es) | 1994-06-30 |
| AU676502B2 (en) | 1997-03-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO934163D0 (no) | HER4 human reseptor-tyrosinkinase | |
| DE69233676D1 (de) | Rezeptor Protein Tyrosin-Kinase (FLK-1) | |
| IL97872A0 (en) | Styryl-substituted monocyclic and bicyclic heteroaryl compounds which inhibit egf receptor tyrosine kinase | |
| BR9206722A (pt) | Antagonista receptores de endotelina | |
| DK0823900T3 (da) | Quinazolinderivater | |
| DK0817775T3 (da) | Quinazolinderivater | |
| DE69327720T2 (de) | Endothelin rezeptor antagonisten | |
| PT8587T (pt) | Assento de seguranca | |
| IL115642A0 (en) | Her4 human receptor tyrosine kinase | |
| ZA945372B (en) | Tyrosine kinase receptor | |
| DE69133436D1 (de) | Protein-tyrosinkinase | |
| DE59205535D1 (de) | Dreschkorb | |
| EP0800531A4 (en) | NEW RECEPTOR TYROSINE KINASE | |
| GB9304708D0 (en) | Human neurokinin-3 receptor | |
| IL110384A0 (en) | Tyrosine kinase receptor | |
| GB2241500B (en) | Human mevalonate kinase | |
| GB9420389D0 (en) | Novel receptor tyrosine kinase | |
| FI971352A (fi) | Sytoplasminen tyrosiinikinaasi | |
| KR930002091U (ko) | 세면기 설치대 | |
| KR930019408U (ko) | 원적외선 발산 침대 | |
| GB9224057D0 (en) | Novel protein kinase receptors | |
| FI934308A0 (fi) | Daemparanlaeggning foer en med tonvaexlingsmekanism foersedd kantele | |
| GB9122316D0 (en) | Quinazoline derivatives | |
| KR970011694U (ko) | 높이조절다리 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC2A | Withdrawal, rejection or dismissal of laid open patent application |